Nanologica Q2 2025: Low near-term visibility but encouraging long-term case - Redeye

Redeye updates its view on Nanologica following the Q2 report. While near-term visibility remains limited, the company continues to build a solid foundation for the long-term case. The potential announcement of new production customers in H2 could pave the way for strong sales growth. Based on our updated estimates, the share is trading at 1.1x 2026e EV/S.

Länk till analysen i sin helhet: https://www.redeye.se/research/1116790/nanologica-q2-2025-low-near-term-visibility-but-encouraging-long-term-case?utm_source=finwire&utm_medium=RSS